US EditionCARsgen Presents Preliminary Results on Satri-cel for Adjuvant Therapy of Pancreatic Cancer at ESMO Congress 2025
- CARsgen presented preliminary results for Satri-cel used in adjuvant therapy for pancreatic cancer at the ESMO Congress 2025.
- The trial included patients with Claudin18.2 positive PDAC, showing an 83.3% disease-free survival rate at nine months post-surgery.
- Dr. Zonghai Li stated that Satri-cel demonstrated promising efficacy with a manageable safety profile for pancreatic cancer treatment.
- Only one patient in the trial experienced disease recurrence after a median follow-up of 6.05 months post-infusion.
68 Articles
68 Articles
LoudounTimes.com
CARsgen Presents Preliminary Results on Satri-cel for Adjuvant Therapy of Pancreatic Cancer at ESMO Congress 2025
SHANGHAI, Oct. 20, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the research results of the Phase Ib registrational clinical trial of satricabtagene autoleucel ("satri-cel", CT041) (an…
CARsgen Satri-cel Phase I Data at ESMO 2025: Early Signal in Adjuvant Pancreatic Cancer
SHANGHAI, Oct. 20, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the research results of the Phase Ib registrational clinical trial of satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product candidate against protein Claudin18.2) for pancreatic cancer (PC) adjuvant therapy in China (CT041-ST-05, NCT05911217…
Coverage Details
Bias Distribution
- 70% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
